# Exact Sciences (Abbott)

Source: https://onco.cc/companies/exact-sciences/  
OnCo record `exact-sciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Exact Sciences makes Cologuard and Oncotype DX and is launching Cancerguard MCED and Oncodetect MRD; it is being acquired by Abbott for $21B.

## Summary

Exact Sciences, based in Madison, Wisconsin, makes Cologuard and Oncotype DX and is launching the Cancerguard multi-cancer early detection test and the Oncodetect residual disease test; Abbott is acquiring it for 21 billion dollars. Its products span Cologuard Plus for stool-based colorectal screening, Oncotype DX for breast cancer recurrence risk, Oncodetect for MRD and Cancerguard, offered as a laboratory-developed test from 2025. OnCo links it to colorectal and HR-positive breast cancer, to MRD testing and multi-cancer early detection, to the early detection roadmap from organ screening to blood tests, and to Abbott Laboratories. Whether the Abbott deal turns a screening franchise into a broader diagnostics platform is the open question. Each product has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Madison, WI
- Type: diagnostics
- Website: https://www.exactsciences.com

## Sources

- Official website: https://www.exactsciences.com

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- drugs: [Cancerguard](https://onco.cc/drugs/cancerguard/), [Cologuard](https://onco.cc/drugs/cologuard/), [Cologuard Plus](https://onco.cc/drugs/cologuard-plus/), [Oncodetect](https://onco.cc/drugs/oncodetect/), [Oncotype DX](https://onco.cc/drugs/oncotype-dx/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- key papers: [Multitarget stool DNA testing for colorectal-cancer screening](https://onco.cc/key-papers/paper-imperiale-multitarget-stool-dna-screening-nejm-2014/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [Multitarget stool RNA test (ColoSense)](https://onco.cc/technologies/multitarget-stool-rna-test/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/), [Early detection roadmap: organ screening → blood tests for many cancers](https://onco.cc/roadmaps/early-detection-roadmap/)
- bottlenecks: [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/)
- trials: [Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer](https://onco.cc/trials/nct06850623/), [BLUE-C](https://onco.cc/trials/blue-c/), [DeeP-C](https://onco.cc/trials/deep-c/)
- companies: [Abbott Laboratories](https://onco.cc/companies/abbott/)

---
JSON: https://onco.cc/api/v1/entities/exact-sciences.json